Sugi Predict

Sugi Predict / Compounds / SCHEMBL458409

SCHEMBL458409

SCHEMBL458409

CC(C)N(C(=O)c1ccccc1)C(C)C

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPSR1 Q6W5P4 3/20 0.59
▸ TRPM8 Q7Z2W7 5/20 0.54
▸ HPGD P15428 3/20 0.53
▸ MCOLN3 Q8TDD5 2/20 0.53
▸ ALDH1A1 P00352 2/20 0.53
▸ LMNA P02545 2/20 0.53
▸ MAPT P10636 2/20 0.53
▸ KDM4E B2RXH2 1/20 0.53
▸ HSD11B1 P28845 1/20 0.50
▸ MLYCD O95822 1/20 0.49
▸ OPRM1 P35372 1/20 0.48
▸ OPRD1 P41143 1/20 0.48
▸ GABRA1 P14867 1/20 0.46
▸ GABRB2 P47870 1/20 0.46
▸ PGR P06401 1/20 0.46
▸ ADRA2A P08913 1/20 0.46
▸ ADRA2B P18089 1/20 0.46
▸ HTR2A P28223 1/20 0.46
▸ HRH1 P35367 1/20 0.46
▸ KCNH2 Q12809 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL31125741 0.98 NPSR1 (0.57) NPSR1TRPM8HPGDMCOLN3ALDH1A1
Hydrochloric Acid SCHEMBL3759428 0.98 NPSR1 (0.57) NPSR1TRPM8HPGDMCOLN3ALDH1A1
SCHEMBL1477108 0.94 NPSR1 (0.54) NPSR1TRPM8HPGDMCOLN3ALDH1A1
Maleic Acid SCHEMBL6137323 0.90 NPSR1 (0.51) NPSR1TRPM8HPGDMCOLN3ALDH1A1
SCHEMBL30268201 0.88 NPSR1 (0.66) NPSR1HPGDMCOLN3ALDH1A1LMNA
SCHEMBL6383907 0.85 NPSR1 (0.50) NPSR1TRPM8HPGDMCOLN3ALDH1A1
SCHEMBL6383709 0.85 NPSR1 (0.50) NPSR1TRPM8HPGDMCOLN3ALDH1A1
SCHEMBL154606 0.84 TRPM8 (0.53) NPSR1TRPM8HPGDALDH1A1LMNA
SCHEMBL1827276 0.84 HPGD (0.56) NPSR1HPGDMCOLN3ALDH1A1LMNA
SCHEMBL29173031 0.83 TRPM8 (0.45) NPSR1TRPM8HPGDMCOLN3ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 387 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118359610-A MENIN-MLL interaction inhibitors 生命医药有限责任公司 2024-07-19 — — CN claimed
CN-117567232-A Extraction separation method of alkyl benzothiophene in beta-methylnaphthalene 中煤科工清洁能源股份有限公司 2024-02-20 — — CN claimed
US-20230405008-A1 TREATMENT OF HEMATOLOGICAL MALIGNANCIES WITH INHIBITORS OF MENIN KURA ONCOLOGY, INC. 2023-12-21 — — US claimed
EP-4232020-A1 TREATMENT OF HEMATOLOGICAL MALIGNANCIES WITH INHIBITORS OF MENIN Kura Oncology, Inc. (US) 2023-08-30 — — EP claimed
CN-112585140-B Optically active azabicyclo derivatives 住友制药株式会社 2023-07-04 — — CN claimed
EP-3512850-B1 INHIBITORS OF THE MENIN-MLL INTERACTION VITAE PHARMACEUTICALS LLC (US) 2023-04-12 — — EP claimed
CN-110139861-B Pyran derivatives as CYP11A1 (cytochrome P450 monooxygenase 11A 1) inhibitors 奥赖恩公司 2022-12-30 — — CN claimed
CN-109743875-B Inhibitors of the MENIN-MLL interaction 生命医药有限责任公司 2022-04-29 — — CN claimed
WO-2022086986-A1 TREATMENT OF HEMATOLOGICAL MALIGNANCIES WITH INHIBITORS OF MENIN KURA ONCOLOGY, INC. (US) 2022-04-28 — — WO claimed
CN-113214552-B Method for manufacturing rubber rain shoes with metallic color effect 杭州星发彩印有限公司 2022-04-05 — — CN claimed
CN-101917845-A Haloallylamine inhibitors of SSAO/VAP-1 and uses therefor PHARMAXIS LTD 2010-12-15 — — CN claimed
CN-1926113-A Novel amido substituted hydroxy-6-phenylphenanthridines and their use as PDE4 inhibitors ALTANA PHARMA AG (DE) 2007-03-07 — — CN claimed
CN-1269805-C 4- (phenyl-piperazinyl-methyl) -benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders ASTRAZENECA AB (SE) 2006-08-16 — — CN claimed
CN-1547579-A 4-(phenyl-piperdin-4-ylidene-methyl)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders — 2004-11-17 — — CN claimed
CN-1527820-A 4-(phenyl-piperazinyl-methyl)benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestional disorders — 2004-09-08 — — CN claimed
CN-1527828-A 4- (phenyl-piperidin-4-ylidene-methyl) -benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders — 2004-09-08 — — CN claimed
CN-1509271-A 4- (phenyl-piperidin-4-ylidene-methyl) -benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders — 2004-06-30 — — CN claimed
EP-1395574-A1 4-(PHENYL-PIPERIDIN-4-YLIDENE-METHYL)-BENZAMIDE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF PAIN, ANXIETY OR GASTROINTESTINAL DISORDERS AstraZeneca AB (SE) 2004-03-10 — — EP claimed
WO-2002094810-A1 4-(PHENYL-PIPERIDIN-4-YLIDENE-METHYL)-BENZAMIDE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF PAIN, ANXIETY OR GASTROINTESTINAL DISORDERS ASTRAZENECA AB (SE) 2002-11-28 — — WO claimed
EP-0518819-B1 Amidino compounds, their manufacture and use as medicament CIBA GEIGY AG (CH) 1995-08-02 — — EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230405008-A1 TREATMENT OF HEMATOLOGICAL MALIGNANCIES WITH INHIBITORS OF MENIN MEN1, MCL1, XPOT NPSR1 4703/4885TRPM8 3259/4885HPGD 2914/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.